ALSUntangled #64: butyrates

Yuyao Sun, Richard Bedlack, Carmel Armon, Morgan Beauchamp, Tulio Bertorini, Robert Bowser, Mark Bromberg, James Caress, Gregory Carter, Jesse Crayle, Merit E. Cudkowicz, Jonathan D. Glass, Carlayne Jackson, Isaac Lund, Sarah Martin, Sabrina Paganoni, Gary Pattee, Dylan Ratner, Kristiana Salmon, Paul Wicks

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review butyrate and its different chemical forms (butyrates). Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.

Original languageEnglish (US)
Pages (from-to)638-643
Number of pages6
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Issue number7-8
StatePublished - 2022


  • ALS
  • alternative therapy
  • butyrate
  • gut microbiome
  • neuroinflammation

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'ALSUntangled #64: butyrates'. Together they form a unique fingerprint.

Cite this